INVESTOR PRESENTATION

Ofer Haviv, President & CEO
March 2022
Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene’s and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.
Agenda

🌟 Introduction
🌟 Fields of activity
🌟 Main subsidiaries
🌟 Summary

Annex I - Technology
Annex II - Financial Fundamentals
OUR VISION

Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies.
Life-science product development
Low probability of success with high cost and long time-to-market

Pharmaceutical Industry

Cost of developing a single pharmaceutical drug

In the 1970’s
$180 million

2000’s – 2017
$2.7 billion

Ag-chemicals Industry

Time to develop a new crop protection product

<table>
<thead>
<tr>
<th>Year</th>
<th>1995</th>
<th>2000</th>
<th>2005-8</th>
<th>2010-15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of years between the first synthesis and first sale of product</td>
<td>8.3</td>
<td>9.1</td>
<td>9.8</td>
<td>11.3</td>
</tr>
</tbody>
</table>

https://www.forbes.com/sites/matthewherper/2017/10/16/the-cost-of-developing-drugs-is-insane-a-paper-that-argued-otherwise-was-insanely-bad/?sh=7533aa826459
Source: Phillips McDougall, 2016
Life-science product development
The ultimate case of a needle in the haystack

|                | Discovery | Optimization | Development | Regulation |
|                |           |              |             |            |
| Agriculture    |           |              |             |            |
| Pharma         |           |              |             |            |

**Product Candidates**

**The challenge:** Finding the winning candidates out of a vast number of possible prospects, that address a complex myriad of criteria to reach successful products.
The opportunity

Utilizing an advanced computational biology platform, to identify the most promising candidates addressing multiple development challenges, towards successful life-science products:

• Increase probability of success
• Reducing time and cost
When biology meets disruptive technologies

Incorporating deep scientific understandings together with big data and advanced artificial intelligence technologies (AI), to successfully discover & guide the development of novel life-sciences based products.

-- Computational Predictive Biology
Tailor-made Engines for product discovery & development

The CPB platform enhances product discovery and development through dedicated Engines for products based on three core components:

- Microbes
- Small molecules
- Genetic elements
Case Study – Potential uses for MicroBoost AI

- Microbials for Crops
- Therapeutic microbials
- Food
- Probiotics
- Human & Animal Probiotics
- Dietary Supplements
- Plastic Degradation
- Chemicals
- Source for Enzymes
- Oil Spill Clearing
- Wastewater Treatments

Developing an eco-system around our tech engines
User Interface
Business Model

1. Establish independent entities focusing on a defined commercial field with an exclusive license to use Evogene’s unique solutions for product development.

Subsidiaries:

- **agPlenus**: Ag-chemicals
- **BIOMICA**: Microbiome based therapeutics
- **CANONIC**: Medical cannabis
- **casterra**: Ag-solutions for castor
- **lavie bio**: Ag-biologicals

Licensed to use Evogene’s technological engines:
Business Model

Collaborations powered by Evogene’s technology for the development of innovative products

Joint development with leading companies for defined products utilizing Evogene’s unique solution. Typically, partner leads later-stage development and product commercialization.

Collaborations for product development:

Powered by Evogene’s technological engines:
Agenda

- Introduction
- **Fields of activity**
- Main subsidiaries
- Summary

Annex I - Technology

Annex II - Financial Fundamentals
Current life-science based products powered by Evogene’s tech-engines

<table>
<thead>
<tr>
<th></th>
<th>HUMAN HEALTH</th>
<th>AGRICULTURE</th>
<th>OTHER INDUSTRIES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MICROBES</strong></td>
<td>Microbiome based Therapeutics</td>
<td>Ag-Biologicals</td>
<td></td>
</tr>
<tr>
<td><strong>SMALL MOLECULES</strong></td>
<td>Drugs based on small molecules</td>
<td>Ag-Chemicals</td>
<td></td>
</tr>
<tr>
<td><strong>GENETIC ELEMENTS</strong></td>
<td>Medical Cannabis</td>
<td>Seed Traits</td>
<td>Ag-solutions for castor oil production</td>
</tr>
</tbody>
</table>
Development & commercialization through subsidiaries and collaborations

<table>
<thead>
<tr>
<th>MICROBES</th>
<th>HUMAN HEALTH</th>
<th>AGRICULTURE</th>
<th>OTHER INDUSTRIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biomica</td>
<td></td>
<td>lavie bio</td>
<td></td>
</tr>
<tr>
<td>Small Molecules</td>
<td></td>
<td>agPlenus</td>
<td></td>
</tr>
<tr>
<td>Genetic Elements</td>
<td></td>
<td>Canonic</td>
<td></td>
</tr>
</tbody>
</table>

* Non-exclusive license
Evogene Group

Human Health

**Biomica**
- Microbiome based Therapeutics
  - Immuno-oncology
  - GI- gastrointestinal-related disorders
  - MDRO – multi-drug resistant organisms

**Canonic**
- Medical Cannabis
  - High yield & consumer traits
  - Therapeutic traits – currently inflammation & pain

**AgPlenus**
- Agriculture
  - Ag Chemicals
    - Herbicides
    - Insecticides
    - Fungicides

**Lavie Bio**
- Ag Biologicals
  - Bio-Stimulants
  - Bio-Pesticides

**Casterra**
- Other Industries
  - Seed Traits
    - Yield improvement and drought tolerance
    - Plant disease
    - Insect control
  - Castor Seed & growth protocols

*Evogene holdings*
## Main Subsidiaries: Industry Landscape

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Market Cap/Funds Raised</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVELO</td>
<td>$166m*</td>
</tr>
<tr>
<td>FINCH</td>
<td>$320m*</td>
</tr>
<tr>
<td>SERES</td>
<td>$651m*</td>
</tr>
<tr>
<td>4D Pharma Pic</td>
<td>$68m*</td>
</tr>
<tr>
<td>CANONIC</td>
<td></td>
</tr>
<tr>
<td>CRESOLABS</td>
<td>$1.6B*</td>
</tr>
<tr>
<td>Curaleaf</td>
<td>$4.3B*</td>
</tr>
<tr>
<td>IMCO</td>
<td>$141m*</td>
</tr>
<tr>
<td>INTERCURE</td>
<td>$290m*</td>
</tr>
<tr>
<td>lavour bio</td>
<td></td>
</tr>
<tr>
<td>biotalys</td>
<td>€192m*</td>
</tr>
<tr>
<td>Marrone Bio Innovations</td>
<td>$126m*</td>
</tr>
<tr>
<td>Pivot Bio</td>
<td>Raised $430m $2.0B# rep. (July 2021)</td>
</tr>
<tr>
<td>agPlenus</td>
<td></td>
</tr>
<tr>
<td>AgBiome</td>
<td>Raised $116m# (Sep 2021)</td>
</tr>
<tr>
<td>AgMetis</td>
<td>Raised $24m# (Jan 2017)</td>
</tr>
<tr>
<td>Enko</td>
<td>Raised $45m# (June 2020)</td>
</tr>
<tr>
<td>Erthbic</td>
<td>Raised $55m# (Feb 2020)</td>
</tr>
<tr>
<td>5Metis</td>
<td>Raised $10m# (Oct 2021)</td>
</tr>
</tbody>
</table>

* Public company – market cap as of March 9, 2022 (yahoo.finance.com)
# Private company – amount raised in most recent financing round (crunchbase.com)

The table presents valuation or amount raised in last financing round for a selected number of companies active in the same industries as our subsidiaries, is not a comprehensive list, and is presented for informational purposes only. There may be significant differences between companies active in each industry, and therefore the table does not indicate potential value for our subsidiaries, which may have no correlation to the information presented in the table and may differ significantly. Such differences may include, among others, company maturity stage, volume of sales, if any, product types, target market segments, pipeline maturity, technology, and financial position.
Agenda

🌟 Introduction
🌟 Fields of activity
🌟 Main subsidiaries
🌟 Summary

Annex I - Technology
Annex II - Financial Fundamentals
Immuno-oncology program:
- Combination therapy for cancer with checkpoint inhibitors
- Pre-clinical stage
- Addressable market size expected by 2026* – $243B

GI related disorders:
- Inflammatory Bowel Disorder (IBD) – pre-clinical stage
- Irritable Bowel Syndrome (IBS) – discovery stage
- Addressable market size expected by 2026: Inflammatory Bowel Disorder $22.4B, Irritable Bowel Syndrome** $3.3B

MDRO:
- Multi Drug Resistant Organisms (antimicrobial resistance)
- Clostridium Difficile Infection (CDI) – discovery stage
- Methicillin-resistant Staphylococcus aureus (MRSA) – discovery stage
- Addressable market size expected by 2026: CDI*** $1.7B, MRSA**** $3.9B

Mission:
Discovery and development of novel therapies for microbiome-related human disorders using computational biology

2022
- IBD - initiate scale-up for GMP production of drug candidate for IBD
- Immuno-oncology - readout from proof of concept, first in human study

2023
- IBD - Clinical batch production of drug candidate for IBD as preparation for Phase 1 in USA
- Immuno-oncology - Pre-IND Meeting with FDA

Example Results:

- Immuno-Oncology program – BMC128 potentiate the effect of anti-PD-1 therapy (immunotherapy) in-vivo

- Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone

- Biomica's live biotherapeutic drug candidate, BMC128, significantly increased anti-tumor activity in combination with Immune Checkpoint Inhibitors in Melanoma. First-in-human, proof of concept study expected later this year

- Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination with Bristol Myers Squibb's Anti-PD-1 Opdivo®

  - Clearance for Proof-of-Concept Phase I human trial in oncology received from Israeli Ministry of Health
Mission:
Commercialize effective, precise and stable medical cannabis products, based on decoding plant genetics, for optimized therapeutic effect

Product Pipeline:

**MetaYield⁺ Products:**
- Stable enhancement of total plant compounds:
  - Increased compounds per plant
  - Increased compounds per area
- Total Cannabis market size expected by 2024 – $42.7B*

**Precise⁺ Products:**
- Stable enhancement of specific active compounds for pain and inflammation:
  - Medical indication focus
  - Compound profile focus
- Total Medical Cannabis market size expected by 2024 – $25.6B*

Expected main near-term value drivers:

2022
- **MetaYield⁺** - commercial launch and sales of second-generation products in Israel
- **Precise⁺** - Collect clinical data to support commercial launch in 2023 of variety reducing pain or inflammation

2023
- **MetaYield⁺** - commercial launch and initial sales of first product in Europe
- **Precise⁺** - Commercial launch of variety reducing pain or inflammation

*Source: Arcview Market Research/BDS Analytics 2020
First Products:
MetaYield products—increased compounds per area, addressing the T20/C4 (17%-24% THC & 1%-7% CBD) and T15/C3 (11%-19% THC & 0.5%-5.5% CBD) market segments.

Medical Cannabis aiming at high THC, high yield, big inflorescence and dense trichomes
**Mission:**
Design next-generation, effective and sustainable crop protection products by leveraging predictive biology & chemistry

**Product Pipeline:**

### Herbicides:
- Novel MoA (Mode-of-Action) selective/non-selective herbicides
- Relevant target crops – Cereals, Rice, Corn, Soybean, Cotton, Canola, Sugar Beet, Other TBD
- Addressable market size expected by 2022*: $34B
- Lead stage

### Insecticides:
- Novel SoA (Site-of-Action)
- Addressable market size expected by 2022*: $19B
- Hit-to-Lead stage

**Expected main near-term value drivers:**

### 2022
- **New MoA Herbicide** – enter an additional collaboration agreement
- **New MoA Herbicide** – expand data package for APTH1, AgPlenus’ leading new MoA protein for the development of novel herbicides

### 2023
- **New MoA Herbicide** – phase advancement in one of the ongoing collaborations
- **New MoA Fungicide program** – initial greenhouse readouts

---

Example Results:
New MoA Herbicide - APH1

Field test of APH1 against a panel of grass and broadleaf weeds – untreated control vs APH1

Greenhouse testing of APH1 – modified tobacco plants with resistance trait vs unmodified control

AgPlenus Announces Reaching a 'Lead' Stage in its Novel Mode-of-Action Herbicide Program

This significant development milestone was achieved following positive results for product candidate APH1 in field tests with commercial level application rates on a broad panel of weeds.

AgPlenus Announces Positive Results for a Herbicide Resistance Trait to its Leading Herbicide Product Candidate

Greenhouse proof-of-concept testing demonstrates resistance of modified model plants to AgPlenus' APH1 herbicide candidate.
**Mission:**
Improve food quality, sustainability and agriculture productivity through microbiome based ag-biologicals technology and products

---

**Product Pipeline:**

<table>
<thead>
<tr>
<th><strong>Bio-stimulants (yield enhancement):</strong></th>
<th><strong>Bio-pesticides (crop protection):</strong></th>
</tr>
</thead>
</table>

---

**Expected main near-term value drivers:**

**2022**
- **Bio-stimulants** – build infrastructure for scale-up in ‘result™’ sales for spring wheat in 2023
- **Fruit rot bio-fungicides** – file for regulatory approval for leading product candidate LAV311 for fruit rot

**2023**
- **Bio-stimulants** – ‘result™’ product sales expansion in US and Canada for spring wheat
- **Bio-fungicides** - file for regulatory approval for leading product candidate LAV321 or LAV322 for downy mildew

---

Example Results:
- result™ inoculant (bio-stimulant)
- LAV 311 & LAV 312 leading bio-fungicide candidates for fruit rot

Lavie Bio’s wheat field in the USA during harvest – initial sales in 2022

Example of treatment against Botrytis Cinerea in vines – untreated control vs treated vines

Lavie Bio Announces Commercial Launch of its First Microbiome-Based Product for Yield Improvement – result™
result™ inoculant initially introduced for spring wheat in North Dakota, following positive four-year field trials

Lavie Bio Reports Advancement in its Bio-Fungicide Program for Fruit Rots
Advancement to the pre-commercial stage follows positive results from three consecutive years of vineyard trials for fruit rot diseases
## Subsidiaries

### Expected main near-term value drivers

<table>
<thead>
<tr>
<th>Subsidiary</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BIOMICA</strong></td>
<td><strong>IBD</strong> – initiate scale-up for GMP production of drug candidate for IBD</td>
<td><strong>IBD</strong> – clinical batch production of drug candidate for IBD as preparation for Phase 1 clinical trials in USA</td>
</tr>
<tr>
<td></td>
<td><strong>Immuno-oncology</strong> – readout from proof-of-concept, first in human study</td>
<td><strong>Immuno-oncology</strong> – pre-IND meeting with FDA</td>
</tr>
<tr>
<td><strong>CANONIC</strong></td>
<td><strong>MetaYield</strong> – commercial launch of second-generation products in Israel</td>
<td><strong>MetaYield</strong> – commercial launch of first product in Europe</td>
</tr>
<tr>
<td></td>
<td><strong>Precise</strong> – collect user data for clinical indications to support commercial launch in 2023</td>
<td><strong>Precise</strong> – commercial launch of first product in Israel</td>
</tr>
<tr>
<td><strong>agPlenus</strong></td>
<td><strong>New MoA herbicides</strong> – enter an additional collaboration agreement</td>
<td><strong>New MoA herbicides</strong> – reach milestone in one of the ongoing collaborations</td>
</tr>
<tr>
<td></td>
<td><strong>New MoA herbicide</strong> – expand data package for APTH1, AgPlenus’ leading new MoA protein for the development of novel herbicides</td>
<td><strong>New MoA fungicide</strong> – initial greenhouse readouts</td>
</tr>
<tr>
<td><strong>lavie bio</strong></td>
<td><strong>Bio-stimulants</strong> – build infrastructure for scale-up in 'result™' sales for spring wheat in 2023</td>
<td><strong>Bio-stimulants</strong> – 'result™' product sales expansion in US and Canada for spring wheat</td>
</tr>
<tr>
<td></td>
<td><strong>Bio-fungicides</strong> – file for regulatory approval for leading product candidate LAV311 for fruit rot</td>
<td><strong>Bio-fungicides</strong> - file for regulatory approval for leading product candidate LAV321 or LAV322 for downy mildew</td>
</tr>
</tbody>
</table>
Agenda

- Introduction
- Fields of activity
- Main subsidiaries
- Summary

Annex I - Technology
Annex II - Financial Fundamentals
140 Employees

30% PhDs

56% Women

- Computational systems biology
- Computational chemistry
- Bioinformatics
- Molecular biology
- Microbiology
- Genetics
- Biochemistry

Incl. chairperson of the board
Our vision - Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies.

CPB platform - a unique technology platform stemming from the incorporation of deep scientific understandings of biology together with big-data and artificial intelligence technologies.

The CPB’s three unique engines target to improve the development of products based on the following core components:
1. MicroBoost AI – for products based on microbes
2. ChemPass AI – for products based on small molecules
3. GeneRator AI – for products based on genetic elements

Dual based business model - utilizing Evogene’s solutions for:
1. Product development & commercialization through subsidiaries
2. Product development & commercialization through collaborations

Four main market-oriented subsidiaries, each with a clear milestone roadmap:
1. Biomica – human-microbiome based therapeutics
2. Canonic – medical cannabis
3. AgPlenus – ag-chemicals
4. Lavie Bio – ag-biologicals

Significant catalysts expected in the next 12 months across the subsidiaries and in Evogene’s technological offering
THANK YOU!
Annex I:
Technology
The **challenge** in creating life-science based products
The **challenge** in creating life-science based products

**Common practice**

**Discovery** – selection of product candidates mainly addressing efficacy
The **challenge** in creating life-science based products

**Common practice**

**Discovery** – selection of product candidates mainly addressing efficacy

**Development** – inefficient optimization & difficulty in addressing a single challenge without impairing others

- X Low probability of success
- X Long time to market
- X High development costs
Evogene’s AI-based solution: Discovery

A multi-attribute computational selection of product candidates, addressing relevant challenges using dedicated training data sets and AI.
Evogene’s AI-based solution: Development

A multi-attribute computational analysis, addressing a specific development challenge of the selected candidate, without impairing its ability to address other product attributes.
Evogene’s AI engines provide tailor-made solutions

**Discovery**
Computational prediction of candidates, to serve as the **product’s core-component**, addressing multiple key product attributes.

**Development**
Computational driven solution for guiding and assessing the optimization process of the **selected core component**, without impairing other key product attributes.
Annex II:
Financial Fundamentals
Key Financials: Balance Sheet

Key Points:
- Consolidated cash position: ~$54 million as of 31.12.2021, of which ~$8 million is appropriated to Lavie Bio
- No bank debt
- Listed on TASE (2007) and NASDAQ (2016)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Current Assets</td>
<td></td>
<td>56,890</td>
<td>51,823</td>
</tr>
<tr>
<td>Long-Term Assets</td>
<td></td>
<td>19,414</td>
<td>20,092</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td></td>
<td><strong>76,304</strong></td>
<td><strong>71,915</strong></td>
</tr>
<tr>
<td>Current Liabilities</td>
<td></td>
<td>6,882</td>
<td>9,676</td>
</tr>
<tr>
<td>Long-Term Liabilities</td>
<td></td>
<td>6,002</td>
<td>5,357</td>
</tr>
<tr>
<td>Equity attributable to equity holders of the Company</td>
<td></td>
<td>54,031</td>
<td>46,045</td>
</tr>
<tr>
<td>Non-controlling interest</td>
<td></td>
<td>9,389</td>
<td>10,837</td>
</tr>
<tr>
<td><strong>Total Liabilities &amp; Shareholders Equity</strong></td>
<td></td>
<td><strong>76,304</strong></td>
<td><strong>71,915</strong></td>
</tr>
</tbody>
</table>